Antimüllerian hormone serum levels: a putative marker for ovarian aging.
about
A validated model of serum anti-müllerian hormone from conception to menopauseAntimüllerian hormone as a predictor of natural fecundability in women aged 30-42 yearsThe Gynecologist Has a Unique Role in Providing Oncofertility Care to Young Cancer PatientsDifferent ovarian stimulation protocols for women with diminished ovarian reserveManagement of endometrial modifications in perimenopausal womenThe ovarian reserve of primordial follicles and the dynamic reserve of antral growing follicles: what is the link?Fertility in women of late reproductive age: the role of serum anti-Müllerian hormone (AMH) levels in its assessmentAnti-Müllerian hormone: ovarian reserve testing and its potential clinical implicationsThe ageing ovary and uterus: new biological insightsAdded value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approachAnti-mullerian hormone as a predictor of time to menopause in late reproductive age womenSerum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic reviewImpact of cancer therapies on ovarian reserveQuantification of anti-Müllerian hormone (AMH) in dried blood spots: validation of a minimally invasive method for assessing ovarian reserveContribution of the rate of change of antimüllerian hormone in estimating time to menopause for late reproductive-age womenThe impact of smoking on antimüllerian hormone levels in women aged 38 to 50 yearsAssociation of BRCA1 Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer RiskAnti-Müllerian hormone: a potential new tool in epidemiologic studies of female fecundabilityBiologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in womenAge related endocrine patterns observed in polycystic ovary syndrome patients vs. ovulatory controls: descriptive data from a university based infertility center.Premature ovarian failure: a review.Is AMH Level, Independent of Age, a Predictor of Live Birth in IVF?Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivorsFSH and its second messenger cAMP stimulate the transcription of human anti-Müllerian hormone in cultured granulosa cells.The Protective Effect of N-Acetylcysteine on Ionizing Radiation Induced Ovarian Failure and Loss of Ovarian Reserve in Female Mouse.Maternal serum anti-Müllerian hormone in Sudanese women with preeclampsia.Assay reproducibility and within-person variation of Müllerian inhibiting substance.Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Müllerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndromeThe effect of diet and cardiovascular risk on ovarian aging in cynomolgus monkeys (Macaca fascicularis)Data-driven assessment of the human ovarian reserve.Maternal antimullerian hormone levels do not predict fetal aneuploidy.Interleukin-1 deficiency prolongs ovarian lifespan in mice.Regulation of anti-Müllerian hormone production in the cow: a multiscale study at endocrine, ovarian, follicular, and granulosa cell levels.Roles for transforming growth factor beta superfamily proteins in early folliculogenesis.Anti-Müllerian hormone levels in the follicular fluid of the preovulatory follicle: a predictor for oocyte fertilization and quality of embryo.The role of anti-Müllerian hormone in female fertility and infertility - an overview.Ovarian reserve and reproductive age may be determined from measurement of ovarian volume by transvaginal sonography.Anti-Müllerian hormone serum values and ovarian reserve: can it predict a decrease in fertility after ovarian stimulation by ART cycles?Genetic variants in anti-Mullerian hormone and anti-Mullerian hormone receptor genes and breast cancer risk in Caucasians and African AmericansThe feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy induced ovarian failure in patient with gynecological malignancies
P2860
Q21135308-268A8B7F-CF69-4F24-AC61-086C34868DB3Q23910016-EF2D4487-83E0-48F3-9F4C-D6A9B5E28B7AQ24596913-1D4B65EE-E2A9-45D6-BEB4-CDD2AAAD5313Q24634342-375EA29F-3364-4FE0-9543-E692DBF45DA1Q26777299-0DF27BAD-643C-4FD1-B016-7007680277F8Q27024729-EF8E5523-9629-4424-AFBA-EFA3D93FC75FQ28077710-02C47B4B-9D14-460B-832D-2FCD52BF1FC6Q28239980-996AAE0A-7D63-4C61-BE73-09B54430B359Q28278102-5629C968-C057-4AAC-B7EA-03E986866412Q28280088-155A61CC-3D77-4162-8FC0-A57E1DE3263BQ28383911-AB4CAF76-4049-4D60-A2B6-8AF48E802867Q28384104-969B48F0-75F5-49FF-97B9-DA46C9D13028Q28384958-271DEAFD-54E4-4BED-AE75-38A18F638F16Q28386434-A17201DB-09C2-4BC5-87CC-A8FED8215762Q28390089-BC6D2B41-7DFB-447A-92DF-F57B5E27C0E0Q28395441-C20FD92F-A652-4F12-B7F2-A0190AAF2A98Q28396126-7470E9B3-AC5B-4BBB-83C6-C0A0B8530302Q28396276-E7728ABC-E0B1-4CA2-99A2-1FB4AB532A3AQ30439646-326302F3-8CAD-4DAB-B527-18D869EFE76EQ31136481-56D6EA88-3C97-4EB5-B1D4-17A918BA2178Q33278956-700898CF-C32B-46D0-B9BD-7C0034A5B93EQ33604947-3AFF9A10-9F7A-4605-8DA0-58B8C07D8EECQ33624886-E9D95624-F3F6-4402-8765-8B95691C4597Q33636964-C03EBF75-58F4-4764-81CD-C4EFE1540975Q33760075-788F2AD6-D1B3-4106-A3A0-90767E060266Q33830898-CD9834A5-9724-4C6C-B796-47A208D9B4CDQ33875907-680D5FD8-ADF9-4C8D-B996-8252F41F4FE5Q33917112-B99A669E-164A-4ABE-B6DF-94E9415D3F41Q33981728-8D66F54B-09D7-44BC-BF2C-ACE96A3E3C6FQ34024795-4103BFEF-8A38-4AF1-ABD7-3F87B6586624Q34070204-BB0F069A-1B55-4688-AE8C-986EDA19F12DQ34120059-E9F04FA8-DEC6-4150-AAC0-ED3DCE40B8B7Q34149740-B19DC9A5-778E-48AC-824B-9957929C2468Q34161992-4DCECF1B-C280-4806-B718-9F27F15C0D39Q34208331-58705B1D-DFD1-4121-A770-78811762A675Q34278051-78D95FB1-C2CD-4F4C-9E98-B92095B06AD5Q34327716-29F62691-56D6-487B-A020-86A174B4A05DQ34415976-73E312E9-0479-4DBB-9CC6-DBF759BAB3C6Q34426520-906FFA2A-7DE3-44F5-96D5-04D4001E631DQ34577007-6FA9FBA5-EEE7-406E-A569-4A297459E016
P2860
Antimüllerian hormone serum levels: a putative marker for ovarian aging.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Antimüllerian hormone serum levels: a putative marker for ovarian aging.
@en
Antimüllerian hormone serum levels: a putative marker for ovarian aging.
@nl
type
label
Antimüllerian hormone serum levels: a putative marker for ovarian aging.
@en
Antimüllerian hormone serum levels: a putative marker for ovarian aging.
@nl
prefLabel
Antimüllerian hormone serum levels: a putative marker for ovarian aging.
@en
Antimüllerian hormone serum levels: a putative marker for ovarian aging.
@nl
P2093
P1476
Antimüllerian hormone serum levels: a putative marker for ovarian aging.
@en
P2093
Annemarie de Vet
Axel P N Themmen
Bart C J M Fauser
Frank H de Jong
Joop S E Laven
P304
P356
10.1016/S0015-0282(01)02993-4
P407
P577
2002-02-01T00:00:00Z